Competitor News

Health IT execs skeptical of Oracle’s lofty vision to build national medical records system

By Heather LandiJun 14, 2022 04:30am OracleCernerInteroperability A unified digital health record system for American patients has long been considered the “holy grail” for the healthcare industry. And, like the medieval legend, it’s been a quest embarked on by countless health IT leaders and industry groups over decades. Oracle Chairman Larry…

Collaborations, Competitor News, Data Partnership, Synthetic Data

Syntegra Partners with TMA Precision Health to Reduce the Diagnostic Odyssey for Rare Disease with Synthetic Data-Enabled Tools

SAN FRANCISCO, June 14, 2022 /PRNewswire/ — Syntegra, a leader in synthetic healthcare data generation, today announced a partnership with TMA Precision Health (TMA), a StartUp Health platform for rare diseases, aimed at using synthetic data to improve the diagnosis of rare disease patients around the world. TMA will leverage Syntegra’s synthetic data engine to…

Collaborations, Competitor News, Data Partnership, Europe, International

Finnish Biobanks (FINBB) Partners with TriNetX to Increase Clinical and Biomedical Trials in Finland

CAMBRIDGE, Mass., June 14, 2022 /PRNewswire/ — TriNetX, LLC, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Finnish Biobanks (FINBB), a cooperative owned by the six largest hospital districts and universities in Finland and the Finnish Institute for Health and Welfare, has joined the…

Academic, Collaborations, Competitor News, Product Updates

mphrX and Mount Sinai Health System join forces to enable real-time clinical data sharing to improve collaboration on operational and care improvement initiatives.

NEW YORK, NY (June 14, 2022) – New York-based Healthcare technology company, mphrX, today announced its partnership with Mount Sinai Health System (Mount Sinai) to deploy mphrX’s Minerva platform to enable real-time clinical data sharing designed to meet the 21st Century Cures Act requirements.  Minerva, a Healthcare Data Platform as a…

Collaborations, Competitor News, Data Partnership, Oncology

Real-World Uptake of FGFR-Alteration Testing and Gene-Targeted Therapy for Patients With Urothelial Cancer

In a study reported in a research letter in JAMA Oncology, Nimgaonkar et al found that less than half of patients with urothelial cancer who had received first-line platinum-based therapy underwent testing for FGFR alterations and that less than half of patients with susceptible alterations received targeted therapy with the FGFR inhibitor erdafitinib….

Collaborations, Competitor News, Data Partnership, Oncology

Teclistamab Provides Substantial Clinical Benefit Over Real-World Physician’s Choice in Triple-Class Exposed R/R Myeloma

Teclistamab was found to have improved effectiveness in terms of progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) vs real-world physician’s choice of therapy in patients with triple-class exposed relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy, according to data from a…

Partner and Collaborator News

Palantir and Google Cloud partner to power data-driven transformations in commercial industries

Enterprises of all shapes and sizes have growing amounts of data available to them, and being able to leverage that data easily and quickly for data-driven operations is increasingly critical to staying competitive. However, integrating, shaping, and analyzing data can be extremely time intensive. To help businesses accelerate their operational…

Collaborations, Competitor News, Data Partnership

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 June 13, 2022 06:30 ET | Source: Centogene NV Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including…